Protein degradation has emerged as one of the hottest areas of therapeutic research. Harnessing the cell’s ability to clear damaged or unwanted proteins, these therapies are being developed for some of the most intractable diseases and redefining what conditions are truly “undruggable.” In the last several years, billions have been invested by Big Pharma in partnership deals to gain access to promising science and drug candidates in this space. With the first clinical candidate on the cusp of entering mid-stage clinical trials and numerous others beginning clinical trials, the field is at an inflection point in its rapid evolution. This panel will explore what companies can do to realize the full potential of this science and ultimately bring these promising therapies to commercialization. Specific topics of exploration will include new degrader technologies, successful partnering models, and emerging preclinical development and regulatory challenges.